The NAMPT Inhibitor FK866 Attenuates DEN-Induced Liver Fibrosis in Mice

Area of Science:

• Hepatology
• Pharmacology
• Biochemistry

Background:

• Chronic liver disease (CLD) is a major global health concern.
• Liver fibrosis is a key pathological process in CLD, with limited effective treatments.
• Nicotinamide phosphoribosyltransferase (NAMPT) plays a role in cellular metabolism and inflammation.

Purpose of the Study:

• To investigate the therapeutic potential of the NAMPT inhibitor FK866 in a mouse model of diethylnitrosamine (DEN)-induced liver fibrosis.
• To elucidate the underlying mechanisms of FK866's action on liver fibrosis.

Main Methods:

• Induction of liver fibrosis in mice using DEN.
• Administration of FK866 to treated mice.
• Assessment of liver injury markers (ALT, AST), histopathological changes, and fibrotic markers (fibronectin, collagen IV, laminin, α-SMA).
• Measurement of NAD+ levels, NAMPT, PARP1, and inflammatory cytokine expression (IL-1β, IL-6, TNF-α, P65).

Main Results:

• DEN-induced liver fibrosis was associated with increased hepatic NAMPT and PARP1 expression.
• FK866 treatment reduced liver injury markers and reversed histopathological damage.
• FK866 suppressed elevated fibrotic markers and inflammatory factors.
• The therapeutic effect correlated with inhibition of NAD+ levels, NAMPT, PARP1, and inflammatory mediators.

Conclusions:

• FK866 demonstrates significant therapeutic potential for treating liver fibrosis.
• Inhibition of NAMPT by FK866 offers a promising strategy to combat liver fibrosis progression.
• The mechanism involves reducing NAD+ levels, NAMPT, PARP1, and inflammation.